Coronary vasospasm induced by cisplatin for seminoma

Sasaki, Wataru; Wada, Hiroshi; Sakakura, Kenichi; Matsuda, Jun; Ibe, Tatsuro; Hayashi, Takekuni; Ueba, Hirohito; Momomura, Shin‐ichi; Fujita, Hideo

doi:10.1002/ccr3.2601

Cited by 7 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was observed that intima-media thickness is higher than the estimated value for age, confirming that cisplatin triggers a degenerative process of the vessel walls, leading to occlusive vascular disease in the long term [ 62 ]. Moreover, cisplatin has the potential risk of delayed onset of vasospastic angina [ 63 ].…”

Section: Platinum Compounds (Cisplatin)mentioning

confidence: 99%

Myocardial Ischemia Related to Common Cancer Therapy—Prevention Insights

Bădescu

Bădulescu

Scripcariu

et al. 2022

Life

View full text Add to dashboard Cite

Modern antineoplastic therapy improves survival and quality of life in cancer patients, but its indisputable benefits are accompanied by multiple and major side effects, such as cardiovascular ones. Endothelial dysfunction, arterial spasm, intravascular thrombosis, and accelerated atherosclerosis affect the coronary arteries, leading to acute and chronic coronary syndromes that negatively interfere with the oncologic treatment. The cardiac toxicity of antineoplastic agents may be mitigated by using adequate prophylactic measures. In the absence of dedicated guidelines, our work provides the most comprehensive, systematized, structured, and up-to-date analyses of the available literature focusing on measures aiming to protect the coronary arteries from the toxicity of cancer therapy. Our work facilitates the implementation of these measures in daily practice. The ultimate goal is to offer clinicians the necessary data for a personalized therapeutic approach for cancer patients receiving evidence-based oncology treatments with potential cardiovascular toxicity.

show abstract

Section: Platinum Compounds (Cisplatin)mentioning

confidence: 99%

Myocardial Ischemia Related to Common Cancer Therapy—Prevention Insights

Bădescu

Bădulescu

Scripcariu

et al. 2022

Life

View full text Add to dashboard Cite

show abstract

“…There are few reports of MI with troponin measurements and documented coronary angiography following cisplatin administration. These reports attributed the ischemic event to CAS [ 82 , 83 , 84 , 85 , 86 ]. Troponin elevation was inconsistently present, but coronary angiography recurrently showed no significant CAD, consistent with MINOCA.…”

Section: Etiology and Mechanisms Of Myocardial Infarction In Cancer P...mentioning

confidence: 99%

“…Troponin elevation was inconsistently present, but coronary angiography recurrently showed no significant CAD, consistent with MINOCA. Notably, one report documented that acetylcholine provocation induced severe coronary vasospasm associated with chest pain and significant ST elevation [ 82 ]. Cisplatin-induced MINOCA via CAS may occur early during the treatment regimen or delayed for years after completing cisplatin treatment [ 82 ].…”

Section: Etiology and Mechanisms Of Myocardial Infarction In Cancer P...mentioning

confidence: 99%

“…Notably, one report documented that acetylcholine provocation induced severe coronary vasospasm associated with chest pain and significant ST elevation [ 82 ]. Cisplatin-induced MINOCA via CAS may occur early during the treatment regimen or delayed for years after completing cisplatin treatment [ 82 ]. Since cisplatin has been associated with type 1 MI due to coronary thrombosis, angiographic assessment (optimally invasive) is advised in patients treated with this agent presenting with apparent ACS [ 11 ].…”

Section: Etiology and Mechanisms Of Myocardial Infarction In Cancer P...mentioning

confidence: 99%

See 1 more Smart Citation

Mechanisms of Myocardial Ischemia in Cancer Patients: A State-of-the-Art Review of Obstructive Versus Non-Obstructive Causes

Balanescu¹,

Bloomingdale²,

Donisan³

et al. 2022

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

In patients with cancer, myocardial infarction (MI) has distinct features and mechanisms compared to the non-oncology population. Triggers of myocardial ischemia specific to the oncology population have been increasingly identified. Coronary plaque disruption, coronary vasospasm, coronary microvascular dysfunction, spontaneous coronary artery dissection, and coronary oxygen supply-demand mismatch are all causes of MI that have been shown to have specific triggers related to either the treatments or complications of cancer. MI can occur in the presence or absence of atherosclerotic coronary artery disease (CAD). MI with nonobstructive CAD (MINOCA) is a heterogeneous syndrome that has distinct pathophysiology and different epidemiology from MI with significant CAD (MI-CAD). Recognition and differentiation of MI-CAD and MINOCA is essential in the oncology population, due to unique etiology and impact on diagnosis, management, and overall outcomes. There are currently no reports in the literature concerning MINOCA as a unified syndrome in oncology patients. The purpose of this review is to analyze the literature for studies related to known triggers of myocardial ischemia in cancer patients, with a focus on MINOCA. We propose that certain cancer treatments can induce MINOCA-like states, and further research is warranted to investigate mechanisms that may be unique to certain cancer states and types of treatment.

show abstract

Cisplatin

2020

Reactions Weekly

View full text Add to dashboard Cite

Coronary vasospasm induced by cisplatin for seminoma

Cited by 7 publications

References 10 publications

Myocardial Ischemia Related to Common Cancer Therapy—Prevention Insights

Myocardial Ischemia Related to Common Cancer Therapy—Prevention Insights

Mechanisms of Myocardial Ischemia in Cancer Patients: A State-of-the-Art Review of Obstructive Versus Non-Obstructive Causes

Cisplatin

Contact Info

Product

Resources

About